# US 2008/0076805 A1 · Acyclic Hydrazides as Cannabinoid Receptor Modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076805 A1
- Document ID: US20080076805A1
- Status: Published application
- Kind: A1
- Application number: 11/661,834
- Filed: 2005-10-03
- Published: 2008-03-27
- Earliest claimed: 2004-10-07
- Inventors: Linus Lin; Ping Liu
- Web page: https://patentgrep.com/patent/US20080076805A1

## CPC

- C07C 255/66: having cyano groups and nitrogen atoms being part of hydrazine or hydrazone groups bound to the same carbon skeleton
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/10: Laxatives
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 243/28: to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
- C07C 243/32: the carbon skeleton containing rings
- C07C 243/36: with acylating carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07D 213/64: attached in position 2 or 6
- C07C 2601/08: the ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders (including smoking cessation), the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

## Claims

### Claim 1

A compound of structural formula I:
or a pharmaceutically acceptable salt thereof, wherein;
R1 is selected from:
(1) hydrogen,
(2) C1-4alkyl,
(3) C3-6cycloalkyl,
(4) C2-4alkenyl, and
(5) C2-4alkynyl;
R2 is selected from:
(1) C1-10alkyl,
(2) C2-10alkenyl,
(3) C2-10alkynyl,
(4) C3-10cycloalkyl,
(5) C3-10cycloalkyl C1-4alkyl,
(6) cycloheteroalkyl,
(7) cycloheteroalkyl C14alkyl
(8) aryl,
(9) aryl C1-10alkyl,
(10) aryl C2-8alkenyl,
(11) diaryl C1-4alkyl,
(12) heteroaryl,
(13) heteroaryl C1-10alkyl,
(14) NRcRd,
wherein each alkyl, alkenyl, and alkynyl is straight or branched chain and unsubstituted or substituted with one to four substituents independently selected from Ra and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to four substituents independently selected from Rb;
Ar1 and Ar2 are independently selected from:
(1) aryl, and
(2) heteroaryl,
wherein aryl and heteroaryl are unsubstituted or substituted with one to four substituents independently selected from Rb;
each Ra is independently selected from:
(1) —ORd,
(2) —NRcS(O)mRd,
(3) halogen,
(4) —SRd,
(5) —S(O)mRd,
(6) —S(O)mNRcRd,
(7) —NRcRd,
(8) —C(O)Rd,
(9) —CO2Rd,
(10) —CN,
(11) —C(O)NRcRd,
(12) —NRcC(O)Rd,
(13) —NRcC(O)ORd,
(14) —NRcC(O)NRcRd,
(15) —CF3, and
(16) —OCF3;
each Rb is independently selected from:
(1) Ra,
(2) C1-10alkyl,
(3) oxo,
(4) aryl,
(5) arylC1-4alkyl,
(6) heteroaryl, and
(7) heteroarylC1-4alkyl;
each Rc and Rd is independently selected from:
(1) hydrogen,
(2) C1-10alkyl,
(3) C2-10alkenyl,
(4) cycloalkyl,
(5) cycloalkyl-C1-10alkyl,
(6) cycloheteroalkyl,
(7) cycloheteroalkyl-C1-10alkyl,
(8) aryl,
(9) heteroaryl,
(10) pyridyl,
(11) pyrimidyl,
(12) aryl-C1-10alkyl, and
(13) heteroaryl-C1-10alkyl, or
Rc and Rd together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N—Rg,
each Rc and Rd may be unsubstituted or substituted with one to three substituents selected from Rh;
each Rg is independently selected from:
(1) hydrogen,
(2) C1-4alkyl,
(3) —C(O)C1-4alkyl,
(4) —C(O)ORd,
(5) —C(O)NRcRd,
(6) —S(O)mRd, and
(7) —S(O)mNRcRd;
each Rh is independently selected from:
(1) halogen,
(2) C1-10alkyl,
(3) —O—C1-4alkyl,
(4) —S—C1-4alkyl,
(5) —S(O)m—C1-4alkyl,
(6) —CN,
(7) —NO2,
(8) —CF3,
(9) —CHF2 and
(10) —OCF3; and
m is selected from 1 and 2.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein:
Ar1 is selected from: phenyl, and pyridyl, wherein phenyl and pyridyl are unsubstituted or substituted with one to three Rb substituents; and
Ar2 is selected from: phenyl, and pyridyl, wherein phenyl and pyridyl are unsubstituted or substituted with one to three Rb substituents,
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein:
Ar1 is para-chlorophenyl and Ar2 is selected from: m-chlorophenyl, m-bromophenyl, and m-cyanophenyl,
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein:
R1 is selected from:
(1) hydrogen,
(2) methyl,
(3) ethyl,
(4) propyl, and
(5) allyl,
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein:
R2 is selected from:
(1) C1-8 alkyl,
(2) C3-6 cycloalkyl,
(3) cycloheteroalkyl,
(4) phenyl,
(5) phenyl C1-3 alkyl,
(6) pyridyl,
(7) pyrimidyl,
(8) pyridyl C1-3 alkyl, and
(9) pyrimidyl C1-3 alkyl,
wherein each alkyl moiety is straight or branched chain and unsubstituted or substituted with one, two or three substituents independently selected from Ra, and each cycloalkyl, cycloheteroalkyl, phenyl, and heteroaryl moiety is unsubstituted or substituted with one, two or three substituents independently selected from Rb;
each Rb is independently selected from:
(1) —ORd,
(2) halogen,
(3) —CN,
(4) —CF3,
(5) —OCF3,
(6) cycloheteroalkyl;
(7) C1-4alkyl,
(8) oxo,
(9) phenyl,
(10) benzyl, and
(11) heteroaryl;
each Rd is independently selected from:
(1) hydrogen,
(2) C1-5alkyl,
(3) —CH2CH═CH2,
(4) cyclohexyl,
(5) cyclopentyl,
(6) cyclopropyl,
(7) cyclobutylmethyl,
(8) cyclopentylmethyl,
(9) cyclohexylmethyl,
(10) pyrrolidinyl,
(11) phenyl,
(12) thiazolyl,
(13) pyridyl,
(14) pyrimidyl,
(15) benzothiazolyl,
(16) benzoxazolyl,
(17) triazolyl,
(18) benzyl, and
(19) pyridyl-methyl-,
wherein each Rd may be unsubstituted or substituted with one to three substituents selected from Rh;
each Rh is independently selected from:
(1) halogen,
(2) methyl,
(3) methoxy,
(4) —S(O)m—C1-4alkyl,
(5) —CN,
(6) —CF3,
(7) —CHF2, and
(8) —OCF3;
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein:
R2 is selected from:
each Rd is independently selected from:
(1) hydrogen,
(2) phenyl,
(3) pyridyl, and
(4) pyrimidyl,
wherein phenyl, pyridyl and pyrimidyl are unsubstituted or substituted with one or two Rh substituents; and
each Rg is independently selected from:
(1) hydrogen,
(2) C1-4alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound according to claim 1, selected from the group consisting of:
(1) N′-[1-(3-chlorophenyl)-2-(4-chlorophenyl)ethyl]-N′-methyl-N-{2-methyl-2-[5-(trifluoromethylpyridin-2-yl)oxy]propanoyl}hydrazide;
(2) N′-[1-(3-bromophenyl)-2-(4-chlorophenyl)ethyl]-N′-methyl-N-{2-methyl-2-[5-trifluoromethypyridin-2-yl)oxy]propanoyl}hydrazide;
(3) N′-[1-(3-bromophenyl)-2-(4-chlorophenyl)ethyl]-N′-methyl-N-(1-phenylcyclopentanecarboxyl)hydrazide;
(4) N′-[1-(3-bromophenyl)-2-(4-chlorophenyl)ethyl]-N′-methyl-N-[(2S)-phenylbutanoyl]hydrazide;
(5) N′-[1-(3-chlorophenyl)-2-(4-chlorophenyl)ethyl]-N′-methyl-N-[(2S)-phenylbutanoyl]hydrazide;
(6) N′-[1-(3-chlorophenyl)-2-(4-chlorophenyl)ethyl]-N′-methyl-N-{2-[5-trifluoromethypyridin-2-yl)oxy]butanoyl}hydrazide;
(7) N′-[1-(3-chlorophenyl)-2-(4-chlorophenyl)ethyl]-N′-allyl-N-{2-methyl-2-[5-trifluoromethypyridin-2-yl)oxy]propanoyl}hydrazide;
(8) N′-[1-(3-chlorophenyl)-2-(4-chlorophenyl)ethyl]-N′-methyl-N-(2-methyl-2-hydroxypropanoyl)hydrazide;
(9) N′-[1-(3-chlorophenyl)-2-(4-chlorophenyl)ethyl]-N′-methyl-N-(2-methyl-2-hydroxypropanoyl)hydrazide;
(10) N′-[1-(3-cyanophenyl)-2-(4-chlorophenyl)ethyl]-N′-methyl-N-{2-methyl-2-[(5-trifluoromethylpyridin-2-yl)oxy]propanoyl}hydrazide;
(11) N′-[1-(3-cyanophenyl)-2-(4-chlorophenyl)ethyl]-N′-methyl-N-[(2S)-phenylbutanoyl]hydrazide;
(12) N′-[1-(3-chlorophenyl)-2-(4-chlorophenyl)ethyl]-N′-propyl-N-{2-methyl-2-[5-trifluoromethypyridin-2-yl)oxy]propanoyl}hydrazide; and
(13) N′-[1-(3-chlorophenyl)-2-(4-chlorophenyl)ethyl]-N-{2-methyl-2-[5-trifluoromethypyridin-2-yl)oxy]propanoyl}hydrazide;
or a pharmaceutically acceptable salt thereof.

### Claim at position 8

8-14. (canceled)

### Claim 15 (depends on 1)

A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 15)

The composition according to claim 15 additionally comprising an HMG-CoA reductase inhibitor.

### Claim 17 (depends on 15)

The composition according to claim 15 additional comprising 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

A method of treating a disease mediated by the Cannabinoid-1 receptor in a subject in need thereof comprising administering a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, schizophrenia, substance abuse disorders relating to opiates, alcohol, marijuana, and nicotine; constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, asthma, and obesity or other eating disorders associated with excessive food intake.

### Claim 20 (depends on 1)

A method of treating obesity in a subject in need thereof comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

A method of reducing body weight in a subject in need thereof comprising administration of a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 1)

A method of maintaining the weight of an obese subject comprising administration of an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

A method of reducing the body weight of a subject at risk for obesity comprising administration of an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 7)

A method of treating obesity in a subject in need thereof comprising administration of a therapeutically effective amount of a compound according to claim 7, or a pharmaceutically acceptable salt thereof.
